ImmunityBio, Inc. (IBRX) Stock Analysis — Probabli.AI
AI-powered analysis for IBRX (ImmunityBio, Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Bullish.
Last price: $6.96 · Market cap: $7.2B · AI outlook: Bullish
ImmunityBio, Inc. showcases outstanding revenue growth, robust development pipelines, and favorable buy-side consensus forecasts. Challenges such as regulatory scrutiny and patent disputes must be monitored closely but do not heavily detract from its long-term bullish outlook. Investors should expect significant price appreciation potential with moderate risk.
Probabilistic 1-Year Outlook
- Bull 48% · Neutral 35% · Bear 17%
- 1-year price estimates — P10: $6 / P50: $10 / P90: $12
- ImmunityBio, Inc. demonstrates strong potential, given its rapid revenue growth estimate, recent positive trial data, and. analyst consensus with a strong buy rating. However, regulatory challenges and recent market…
5-Year Outlook
- Bull 60% · Neutral 25% · Bear 15%
- 5-year price estimates — P10: $8 / P50: $18 / P90: $25
SWOT Highlights
- Strength: Strong revenue growth trajectory.
- Strength: Encouraging trial results for novel therapies.
- Risk: Negative recent price performance and volatility.
- Risk: Regulatory challenges including SEC investigation.
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
7 Wall Street analysts rate IBRX a STRONG BUY with a mean price target of $12.57.
Last analyzed · Model: gpt-4o. How this forecast works · Accuracy & validation.
IBRX forecast details · IBRX sentiment details · IBRX insider activity
Recent saved forecast research
AI-generated research records, not evaluated investment results.
- ImmunityBio, Inc. (IBRX) — saved
ImmunityBio, Inc. showcases outstanding revenue growth, robust development pipelines, and favorable buy-side consensus forecasts. Challenges such as regulatory scrutiny and patent disputes must be monitored closely but do not heavily detrac
- ImmunityBio, Inc. (IBRX) — saved
ImmunityBio, Inc., with its innovative pipeline focusing on CAR-T therapy and COVID-19 vaccine potential, is well-positioned within the biotech space. Despite financial and regulatory challenges, the strong growth potential, significant tai
- ImmunityBio, Inc. (IBRX) — saved
ImmunityBio, Inc. (IBRX) is positioned for strong growth given its innovative pipeline in immunotherapy and oncology. High revenue growth estimates and positive analyst targets further reinforce a bullish outlook. However, challenges such a
- ImmunityBio, Inc. (IBRX) — saved
ImmunityBio, Inc. (IBRX) presents a compelling investment case with its strong revenue growth prospects, innovative pipeline, and supportive analyst sentiment. Potential risks arise from patent expirations and dependency on the success of k
- ImmunityBio, Inc. (IBRX) — saved
ImmunityBio, Inc. exhibits strong growth potential due to its innovative cancer treatments, strategic collaborations, and promising revenue forecasts. Despite recent legal challenges and leadership changes, its strengths in clinical trial s
- ImmunityBio, Inc. (IBRX) — saved
ImmunityBio is a robust player in the biotech sector, leveraging strong fundamentals and exciting pipeline developments. Despite challenges such as high competition and unprofitability, its near-term revenue growth estimates and strong anal
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.